Spain’s medicines agency has published the first official guidance for medical cannabis preparations, confirming that its incoming market will exclude raw cannabis flower in favour of ‘standardised’ oral solutions prepared exclusively in hospital pharmacies.
The European medical cannabis industry is continuing to mature, seeing companies focused on science-based research push the boundaries of our understanding of its use cases, and more importantly, fill the long-maligned gap in clinical evidence.
As Europe’s medical cannabis market shifts from a focus on growth to pharmaceutical discipline, PHCANN International has emerged as a leading voice in this new phase.
Amid rising global scrutiny of the wider medical cannabis prescription model, and with markets like France leaning into pharmaceutical-grade regulation, the pharma cannabis sector is shaping up to be one of the most dynamic and closely watched corners of the industry.
At its core, Standard Seed AI’s technology has the power to scientifically validate the entourage effect, streamline drug discovery, and drastically reduce the time and cost of bringing cannabis-based medicines to market.
We’ve summarised the key insights from the vibrant and diverse discussions throughout the second part of Day 1 of Cannabis Europa 2025. If you’re keen to dive into the details, we’ll be exploring each session in more detail over the coming weeks.
Today, Cannabis Europa 2025 welcomed hundreds of the world’s leading cannabis voices for its first jam packed day of sessions.
FURTHER evidence of pharmaceutical interest in the European cannabis space has emerged with German business Dermapharm Holding acquiring Canopy Growth subsidiary C³ Group.
COMBINED sales of the three most lucrative cannabis pharmaceuticals products – Epidiolex, Dronabinol and Sativex – are set to reach €1.8 billion by 2025, according to a new report.
